Published: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 626 to 650 of 797

Sort by

Guidance programme: Technology appraisal guidanceRemove Guidance programme: Technology appraisal guidance filter

Published guidance, NICE advice and quality standards
Title	Reference number	Published	Last updated
Secukinumab for treating moderate to severe plaque psoriasis	TA350	22 July 2015	22 July 2015
Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy (terminated appraisal)	TA351	22 July 2015	22 July 2015
Omalizumab for previously treated chronic spontaneous urticaria	TA339	8 June 2015	8 June 2015
Vedolizumab for treating moderately to severely active ulcerative colitis	TA342	5 June 2015	5 June 2015
Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism	TA341	4 June 2015	4 June 2015
Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia	TA343	2 June 2015	2 June 2015
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome	TA335	25 March 2015	25 March 2015
Empagliflozin in combination therapy for treating type 2 diabetes	TA336	25 March 2015	25 March 2015
Rifaximin for preventing episodes of overt hepatic encephalopathy	TA337	25 March 2015	25 March 2015
Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy	TA329	25 February 2015	25 February 2015
Sofosbuvir for treating chronic hepatitis C	TA330	25 February 2015	25 February 2015
Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment	TA333	25 February 2015	25 February 2015
Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal)	TA334	25 February 2015	25 February 2015
Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma	TA269	12 December 2012	1 January 2015
Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism	TA327	17 December 2014	17 December 2014
Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy	TA323	26 November 2014	26 November 2014
Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block	TA324	26 November 2014	26 November 2014
Nalmefene for reducing alcohol consumption in people with alcohol dependence	TA325	26 November 2014	26 November 2014
Imatinib for the adjuvant treatment of gastrointestinal stromal tumours	TA326	26 November 2014	26 November 2014
Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome and/or atrioventricular block	TA88	23 February 2005	1 November 2014
Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma	TA321	22 October 2014	22 October 2014
Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis	TA320	27 August 2014	27 August 2014
Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen	TA316	23 July 2014	23 July 2014
Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes	TA317	23 July 2014	23 July 2014
Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma	TA319	23 July 2014	23 July 2014

Results per page

10
25
50
All